![]() |
Volumn 1, Issue 2, 2003, Pages 259-266
|
The effect of new drug approvals on HIV mortality in the US, 1987-1998
|
Author keywords
Antiretroviral therapy; HIV drug approval; HIV mortality; Innovation; Pharmaceuticals; R D
|
Indexed keywords
ABACAVIR;
AMPRENAVIR;
ANTIRETROVIRUS AGENT;
DELAVIRDINE;
DIDANOSINE;
EFAVIRENZ;
INDINAVIR;
LAMIVUDINE;
NELFINAVIR;
NEVIRAPINE;
OCTREOTIDE;
PROTEINASE INHIBITOR;
RITONAVIR;
SAQUINAVIR;
STAVUDINE;
ZALCITABINE;
ZIDOVUDINE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ARTICLE;
CAUSE OF DEATH;
DRUG APPROVAL;
DRUG COST;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MORTALITY;
UNITED STATES;
HUMAN;
STANDARD;
STATISTICAL MODEL;
ANTI-HIV AGENTS;
DRUG APPROVAL;
HIV INFECTIONS;
HUMANS;
MODELS, STATISTICAL;
MORTALITY;
UNITED STATES;
|
EID: 0346620161
PISSN: 1570677X
EISSN: None
Source Type: Journal
DOI: 10.1016/S1570-677X(02)00031-X Document Type: Article |
Times cited : (23)
|
References (10)
|